Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10783358 | 0.91 | CYP3A4 (0.43) | CYP3A4ALDH1A1RAPGEF4KMT2AFKBP1A | |
| SCHEMBL89325 | 0.88 | — | — | |
| Water SCHEMBL28511306 | 0.85 | CYP3A4 (0.54) | CYP3A4ALDH1A1RAPGEF4LMNAAGTR1 | |
| SCHEMBL1313272 | 0.85 | CYP3A4 (0.54) | CYP3A4ALDH1A1RAPGEF4LMNAAGTR1 | |
| SCHEMBL3222464 | 0.84 | ALKBH3 (0.49) | CYP3A4ALDH1A1RAPGEF4KMT2AMEN1 | |
| SCHEMBL788090 | 0.82 | FLT1 (0.51) | CYP3A4ALDH1A1KMT2AFKBP1ASMN1; SMN2 | |
| SCHEMBL29059443 | 0.80 | ALDH1A1 (0.46) | CYP3A4ALDH1A1SMN1; SMN2L3MBTL1AGTR1 | |
| Acetic Acid SCHEMBL29059324 | 0.80 | ALDH1A1 (0.46) | CYP3A4ALDH1A1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL1169703 | 0.78 | SMN1; SMN2 (0.49) | CYP3A4KMT2AFKBP1ASMN1; SMN2PTGS2 | |
| SCHEMBL27622138 | 0.78 | CYP3A4 (0.79) | CYP3A4ALDH1A1KMT2AMEN1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103596925-A | Benzocycloheptene acetic acids | HOFFMANN LA ROCHE | 2014-02-19 | — | — | CN | disclosed |
| CN-102056919-A | Substituted sulfonamide derivatives | GRUENENTHAL GMBH | 2011-05-11 | — | — | CN | disclosed |
| CN-1972918-B | Pyrimidine derivatives | HOFFMANN LA ROCHE | 2010-10-13 | — | — | CN | disclosed |
| CN-101035762-B | Alkil-pyridines as 11-beta inhibitors for diabetes | HOFFMANN LA ROCHE | 2010-09-29 | — | — | CN | disclosed |
| CN-100589803-C | Aryl-pyridine derivatives | HOFFMANN LA ROCHE | 2010-02-17 | — | — | CN | disclosed |
| US-7635775-B2 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2009-12-22 | — | — | US | disclosed |
| CN-101511783-A | N-biaryl (hetero) arylsulphonamide derivatives useful in the treatment of diseases mediated by lymphocytes interactions | NOVARTIS AG (CH) | 2009-08-19 | — | — | CN | disclosed |
| EP-1572678-A4 | SUBSTITUTED N-PHENYL SULFONAMIDE BRADYKININ ANTAGONISTS | ELAN PHARM INC (US) | 2008-05-07 | — | — | EP | disclosed |
| CN-100361992-C | Sulfonamide substituted xanthine derivatives for use as PEPCK inhibitors | HOFFMANN LA ROCHE (CH) | 2008-01-16 | — | — | CN | disclosed |
| CN-101035762-A | Alkil-pyridines as 11-beta inhibitors for diabetes | HOFFMANN LA ROCHE (CH) | 2007-09-12 | — | — | CN | disclosed |
| EP-1572678-A2 | SUBSTITUTED N-PHENYL SULFONAMIDE BRADYKININ ANTAGONISTS | Elan Pharmaceuticals, Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1501807-A1 | SULFONYLQUINOXALONE ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ ANTAGONISTS | Elan Pharmaceuticals, Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040147519-A1 | Sulfonylquinoxalone acetamide derivatives as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
| US-20040147520-A1 | Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
| WO-2004056319-A2 | SUBSTITUTED N-PHENYL SULFONAMIDE BRADYKININ ANTAGONISTS | ELAN PHARMACEUTICALS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| WO-2003093245-A1 | SULFONYLQUINOXALONE ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ ANTAGONISTS | ELAN PHARMACEUTICALS, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
| CN-1331674-A | Sulfonamide hydroxamates | HOFFMANN LA ROCHE (CH) | 2002-01-16 | — | — | CN | disclosed |
| CN-1165144-A | Phosphosulfonate herbicides | ROHM & HAAS (US) | 1997-11-19 | — | — | CN | disclosed |
| CN-1165143-A | Phosphosulfonate herbicides | ROHM & HAAS (US) | 1997-11-19 | — | — | CN | disclosed |
| CN-1066266-A | PHOSPHOSULFONATE HERBICIDES | ROHM & HAAS (US) | 1992-11-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147519-A1 | Sulfonylquinoxalone acetamide derivatives as bradykinin antagonists | BDKRB2, BDKRB1, HRH2 | CYP3A4 2687/4885ALDH1A1 2364/4885RAPGEF4 1222/4885 |
| US-20040147520-A1 | Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists | BDKRB2, BDKRB1, PDXK | CYP3A4 2150/4885ALDH1A1 2366/4885RAPGEF4 1842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.